Ngm Biopharmaceuticals Inc.

Colorectal Cancer and Cancer Cachexia

Clinical research in this area focuses on colorectal cancer complicated by cancer cachexia, with attention to changes in body weight, nutritional status, and disease-related wasting.

  • Body weight maintenance
  • Cachexia management
  • Supportive oncology

The therapeutic interest in this disease setting centers on improving the clinical burden associated with cancer-related metabolic decline.

Advanced or Metastatic Solid Tumors

The sponsor is involved in studies of advanced and metastatic solid tumors, reflecting a broad oncology focus across difficult-to-treat malignancies.

  • Solid tumor oncology
  • Metastatic disease
  • Antitumor activity

These trials address tumor control and treatment tolerability in patients with advanced cancer.

Immuno-Oncology

Research activity includes immuno-oncology approaches, with investigation of combination treatment strategies in advanced malignancies.

  • Immune-based cancer therapy
  • Combination treatment
  • Tumor immune response

This area reflects interest in leveraging immune mechanisms to address resistant or progressive cancers.

Oncology Safety and Tolerability

The clinical portfolio also emphasizes safety and tolerability assessment in cancer populations, particularly in studies involving advanced disease.

  • Treatment safety
  • Tolerability assessment
  • Clinical monitoring

These investigations support the evaluation of therapeutic use in patients with substantial disease burden.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of NGM120 in patients with colorectal cancer and cancer cachexia: Evaluating effects on body weight

    Recruiting

    2 1
    Investigated diseases:
    Bulgaria Czechia Hungary Poland Slovakia
  • Study of NGM707 and Pembrolizumab for Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1
    Investigated drugs:
    France Italy Spain